Why the study?
Anticoagulants are primary for venous thromboembolism treatment and prevention, but their clinically standardized application remains controversial.
Do various anticoagulants improve efficacy and safety outcomes in patients requiring treatment or prevention of venous thromboembolism?
Population
119,417 patients across 58 treatment trials and 225,414 patients across 125 prevention trials
Comparison
Various anticoagulants vs placebo or each other
Design
Systematic review and network meta-analysis of randomized controlled trials
Authors
Loading...
TIs and NOACs should be prioritized for VTE prevention and treatment; confirms their top-ranked efficacy and safety in network meta-analysis of RCTs.
Do various anticoagulants improve efficacy and safety outcomes in patients requiring treatment or prevention of venous thromboembolism?
Direct thrombin inhibitors and NOACs are highly effective for VTE prevention and treatment with favorable safety profiles, though apixaban showed superior safety regarding major bleeding compared to rivaroxaban.
Fu et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: